The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Number needed to treat/harm (NNT/NNH): A benefit/risk analysis of fruquintinib vs other treatments for metastatic colorectal cancer (mCRC).
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Abbvie; Agenus; Amgen (I); Boehringer Ingelheim; Bristol Myers Squibb Foundation; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; Merck; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Dirk Arnold
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca; Boston Scientific; CRA International; Gilead Sciences; Janssen; Merck; Onkowissen; Phanes Therapeutics; Seagen; Taiho Pharmaceutical; TERUMO
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Amgen; Aptitude Medical; Art Tempi; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Clinical Cancer Research; Eisai; GlaxoSmithKline; Imedex; iOMEDICO; Merck; PeerMD; PRMA; Sanofi; SERVIER; Sirtex Medical; streamitu; Tactics; Viatris; WebMD
 
Joleen Hubbard
Employment - Allina Health Cancer Institute
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Incyte; Taiho Oncology
Speakers' Bureau - Incyte
Research Funding - BioNTech SE (Inst); C4 Therapeutics (Inst); Exact Sciences (Inst)
 
Lucy Chen
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Ziji Yu
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER